Broad proprietary technology platform that yields potent vaccines.
VaxInnate's vaccines rely upon the company's proprietary TLR technology, which combines proteins of bacterial flagellin with vaccine antigen and leads to a more potent vaccine than just administering the two components simultaneously but unattached. Because of its superior immunogenicity, VaxInnate's vaccine could provide better protection to high-risk populations, provide better protection to healthy persons and do all of this at a lower dose. This platform has broad application into other infectious diseases.
Influenza vaccines that are well suited for stockpiling.
VaxInnate's influenza vaccines use antigens, or parts of antigens, that are found across many strains of virus. Because of this approach, health officials could stockpile with greater certainty that the vaccine will be effective against whatever strain is identified.
Efficient and cost-effective production method that eliminates risks of traditional vaccine manufacture.
VaxInnate's bacterial production method is more efficient and cost-effective than current flu vaccine production techniques. Furthermore, the company's approach to manufacture can eliminate many risks associated with flu vaccine production. VaxInnate's is a clean process.
Strong management team leads vision for company.
VaxInnate's management team has deep experience in the development, formulation, regulatory approval, manufacturing and marketing of vaccines.